Sharp, a global leader in contract packaging, clinical supply services and small-scale sterile manufacturing, has announced plans for the expansion of its Macungie, PA site in North America to increase its production capacity for sterile injectables.
Berry Global Group has invested in additional assets and manufacturing capabilities to increase its healthcare production capacity by up to 30% across three of its European sites.
FUJIFILM Corporation have announced an investment of $1.2 billion in its Large-Scale Cell Culture CDMO Business to further expand the planned FUJIFILM Diosynth Biotechnologies end-to-end bio-manufacturing facility in Holly Springs, North Carolina.
Speaking at an event in Edinburgh, Chris Dougray, Head of Development at CBRE Scotland, and Chris Williams, CBRE’s Head of Life Sciences, joined forces to examine the burgeoning sector’s place in Scotland.
Bristol Myers Squibb have announced a $400 million investment in their Dublin 15 Cruiserath Campus towards the build and design of a Sterile Drug Product facility.
Gerresheimer, a manufacturer for the pharma and life science industry, will invest more than $88 million in expanding its manufacturing operations in Peachtree City, creating over 200 new jobs for Fayette County.
EirGen Pharma has announced the commencement of works in its new plant in the IDA Industrial Estate, including a €20 million internal refit and additional Plant rooms expanding its Oral Solid Dose manufacturing and packaging capabilities.
WuXi AppTec have announced the commissioning of two new peptide manufacturing plants, one at its Changzhou facility and another at the new Taixing site in China.
Novartis recently announced that it has received approval from the US FDA for commercial manufacturing of Pluvicto at its new large-scale, state-of-the-art radioligand therapy (RLT) manufacturing facility in Indianapolis, Indiana, United States.
As we move into 2024, life sciences real estate managers will need to consider sustainability, funding, investor consolidation, and planning regulations as top priorities.
